spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Saphris 

 HSMN NewsFeed - 13 Mar 2015
Actavis Receives FDA Approval of SAPHRIS(R) for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals
 HSMN NewsFeed - 31 Aug 2009
Merck CEO Announces Structure and Global Leadership Team for New Merck
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jul 2009
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 2 Jun 2009
Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Feb 2009
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2009
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.